The proportion of patients with solid tumors who had neutralizing antibodies against the omicron variant rose from 37% after 2 vaccine doses to 90% after 3 doses.
All articles by Andrea S. Blevins Primeau, PhD, MBA
Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.
More than half of patients responded, and responses deepened over time.
Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.
Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.
A phase 2 trial demonstrated tumor shrinkage and improvement in reported outcomes in children with inoperable plexiform neurofibromas associated with neurofibromatosis type 1.